Ultragenyx Pharmaceutical Inc  

(Public, NASDAQ:RARE)   Watch this stock  
Find more results for RARE
111.08
-0.54 (-0.48%)
Sep 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 108.14 - 113.92
52 week 38.01 - 137.05
Open 110.00
Vol / Avg. 709,479.00/508,620.00
Mkt cap 4.32B
P/E     -
Div/yield     -
EPS -2.48
Shares 38.68M
Beta     -
Inst. own 85%
Nov 9, 2015
Q3 2015 Ultragenyx Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 9, 2015
Ultragenyx Pharmaceutical Inc at Robert W Baird and Co Health Care Conference - 8:30AM EDT - Add to calendar
Aug 13, 2015
Q2 2015 Ultragenyx Pharmaceutical Inc Earnings Call - Webcast
Aug 13, 2015
Q2 2015 Ultragenyx Pharmaceutical Inc Earnings Release
Aug 12, 2015
Ultragenyx Pharmaceutical Inc at Canaccord Genuity Growth Conference
Aug 11, 2015
Ultragenyx Pharmaceutical Inc at Wedbush PacGrow Healthcare Conference
Jun 24, 2015
Ultragenyx Pharmaceutical Inc at JMP Securities Life Sciences Conference
Jun 18, 2015
Ultragenyx Pharmaceutical Inc Annual Shareholders Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -34.19% -46.43%
Return on average equity -36.18% -117.34%
Employees 173 -
CDP Score - -

Address

60 Leveroni Ct
NOVATO, CA 94949-5746
United States - Map
+1-415-4838800 (Phone)
+1-415-4838810 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Officers and directors

Emil D. Kakkis M.D., Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Shalini Sharp Senior Vice President, Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Sunil Agarwal M.D. Chief Medical Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Jayson Donald Alexander Dallas Senior Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Dennis Huang Chief Technical Operations Officer and Senior Vice President
Bio & Compensation  - Reuters
Thomas Kassberg Senior Vice President, Chief Business Officer
Age: 54
Bio & Compensation  - Reuters
John Pinion Chief Quality Operations Officer and Senior Vice President, Analytical Sciences and Research
Bio & Compensation  - Reuters
William E. Aliski Independent Director
Age: 67
Bio & Compensation  - Reuters
Matthew K. Fust Independent Director
Age: 50
Bio & Compensation  - Reuters
Michael A. Narachi Independent Director
Age: 55
Bio & Compensation  - Reuters